Checkmate Pharmaceuticals, Inc. (CMPI) Financial Statements (2024 and earlier)

Company Profile

Business Address 245 MAIN STREET, 2ND FLOOR
CAMBRIDGE, MA 02142
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

3/31/2022
Q1
12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including: 80,800,00095,600,000111,500,000125,900,000137,340,000
Cash and cash equivalents 53,494,00063,110,00039,127,00043,055,000137,340,000
Short-term investments      
Other undisclosed cash, cash equivalents, and short-term investments 27,306,00032,490,00072,373,00082,845,000 
Restricted cash and investments 20,00020,00020,00020,00020,000
Other undisclosed current assets 7,851,000(4,546,000)(17,460,000)(23,819,000)6,705,000
Total current assets: 88,671,00091,074,00094,060,000102,101,000144,065,000
Noncurrent Assets
Property, plant and equipment 668,000367,000   
Long-term investments and receivables   10,240,00025,647,00030,973,000 
Long-term investments   10,240,00025,647,00030,973,000 
Other noncurrent assets      
Total noncurrent assets: 668,00010,607,00025,647,00030,973,000 
TOTAL ASSETS: 89,339,000101,681,000119,707,000133,074,000144,065,000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 7,812,0006,702,0007,311,0007,875,0008,860,000
Accounts payable 2,521,0002,198,0002,086,0002,297,0003,706,000
Accrued liabilities 5,291,0004,504,0005,225,0005,578,0005,154,000
Total current liabilities: 7,812,0006,702,0007,311,0007,875,0008,860,000
Noncurrent Liabilities
Total liabilities: 7,812,0006,702,0007,311,0007,875,0008,860,000
Equity
Equity, attributable to parent 81,527,00094,979,000112,396,000125,199,000135,205,000
Common stock 2,0002,0002,0002,0002,000
Additional paid in capital 269,662,000268,179,000266,676,000265,342,000264,344,000
Accumulated other comprehensive loss (2,000)(33,000)(83,000)(74,000) 
Accumulated deficit (188,135,000)(173,169,000)(154,199,000)(140,071,000)(129,141,000)
Total equity: 81,527,00094,979,000112,396,000125,199,000135,205,000
TOTAL LIABILITIES AND EQUITY: 89,339,000101,681,000119,707,000133,074,000144,065,000

Income Statement (P&L) (USD)

3/31/2022
Q1
12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
Operating expenses (14,980,000)(18,955,000)(14,181,000)(10,977,000)(9,833,000)
Operating loss: (14,980,000)(18,955,000)(14,181,000)(10,977,000)(9,833,000)
Nonoperating income (expense) 14,000(15,000)53,00047,0004,000
Investment income, nonoperating 14,00020,00053,00047,0004,000
Loss from continuing operations: (14,966,000)(18,970,000)(14,128,000)(10,930,000)(9,829,000)
Loss before gain (loss) on sale of properties:(14,966,000)(18,970,000)(14,128,000)(10,930,000)(9,829,000)
Net loss attributable to parent: (14,966,000)(18,970,000)(14,128,000)(10,930,000)(9,829,000)
Preferred stock dividends and other adjustments      (1,584,000)
Net loss available to common stockholders, diluted: (14,966,000)(18,970,000)(14,128,000)(10,930,000)(11,413,000)

Comprehensive Income (USD)

3/31/2022
Q1
12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
Net loss: (14,966,000)(18,970,000)(14,128,000)(10,930,000)(9,829,000)
Comprehensive loss: (14,966,000)(18,970,000)(14,128,000)(10,930,000)(9,829,000)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent 31,00050,000(9,000)(74,000) 
Comprehensive loss, net of tax, attributable to parent: (14,935,000)(18,920,000)(14,137,000)(11,004,000)(9,829,000)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: